Outlook Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference

Rhea-AI Summary

Outlook Therapeutics, Inc. (Nasdaq: OTLK) announced that C. Russell Trenary, its CEO, will participate in a fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The company is focusing on developing ONS-5010/LYTENAVA™, the first FDA-approved ophthalmic formulation of bevacizumab for retinal diseases. A video webcast of the chat will be available on-demand starting September 13 at 7:00 AM ET. The company aims to submit its BLA for ONS-5010 to the FDA, positioning itself as a leader in treating retinal indications.

ISELIN, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that C. Russell Trenary, President and Chief Executive Officer of Outlook Therapeutics, will participate in a fireside chat during the virtual H.C. Wainwright 23^rd Annual Global Investment Conference being held September 13 – 15, 2021.

In addition to the fireside chat, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the conference, please visit the conference website.

A video webcast of the fireside chat will be available for viewing on-demand beginning Monday, September 13, 2021 at 7:00 AM ET for those registered for the event and accessible on the Events page in the Investors section of the Outlook Therapeutics website (outlooktherapeutics.com) for 90 days.

About Outlook Therapeutics, Inc.        

Outlook Therapeutics is a biopharmaceutical company working to develop and launch ONS-5010/ LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 ophthalmic bevacizumab is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan and other markets. Outlook Therapeutics expects to submit ONS-5010 ophthalmic bevacizumab to the U.S. FDA as a BLA under the PHSA 351(a) regulatory pathway. For more information, please visit www.outlooktherapeutics.com.

CONTACTS:
Media Inquiries:
Harriet Ullman
Vice President
LaVoie Health Science
T: 617-669-3082
hullman@lavoiehealthscience.com

Investor Inquiries:       
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 833.475.8247 
OTLK@jtcir.com 

 

FAQ

What is the significance of OTLK's participation in the H.C. Wainwright 23rd Annual Global Investment Conference?

OTLK's participation highlights its commitment to engaging with the investor community and sharing updates on its developments, especially regarding ONS-5010.

When will the fireside chat featuring OTLK's CEO take place?

The fireside chat will occur during the H.C. Wainwright Conference from September 13 to September 15, 2021.

What is ONS-5010, and why is it important for Outlook Therapeutics?

ONS-5010 is the first FDA-approved ophthalmic formulation of bevacizumab aimed at treating retinal diseases such as wet AMD, which could position OTLK as a market leader.

How can investors access the video webcast of OTLK's fireside chat?

Investors can access the video webcast on-demand starting September 13 at 7:00 AM ET through the Events page on OTLK's website.

What does OTLK plan to do with the application for ONS-5010?

OTLK plans to submit a Biologics License Application (BLA) to the FDA for ONS-5010 under the PHSA 351(a) regulatory pathway.